The French National Agency for Medicines and Health Products Safety (ANSM) announced on Monday, February 23, the recall of several batches of Doliprane (paracetamol) intended for infants and young children.

Defective dosing pipettes are to blame

The recall concerns bottles of 2.4% oral suspension supplied with dosing pipettes. According to the ANSM (French National Agency for Medicines and Health Products Safety), some pipettes have a defect: their graduations can disappear when washed with warm or hot water.

This alteration can lead to dosage errors and expose children to a risk of paracetamol overdose.

The agency clarifies, however, that the quality of the drug itself is not in question.

27 lots concerned

Opella Healthcare France has recalled 27 batches, numbered L033 to L062. The expiry dates range from August to October 2027.

These products were marketed in pharmacies between November 12, 2025 and February 3, 2026.

The detailed list of affected batches is available on the ANSM website.

Parents in possession of one of the affected batches are advised to stop using the pipette provided; not to replace it with that of another medication; to return the bottle to their pharmacy for an exchange.

If there is any doubt about the dose administered or if the child presents unusual symptoms, it is recommended to consult a doctor promptly.

The defect has been fixed, and no shortage is expected.

The source of the problem was identified at a specific production site and has since been corrected. The ANSM (French National Agency for Medicines and Health Products Safety) assures that no defects have been found in pipettes from other sites.

To date, no adverse effects related to this defect have been reported. The laboratory also specifies that there is no risk of supply disruption.